[1,3]二氧杂环戊并[4,5-f][1,3]苯并噻唑-6-胺 | 50850-94-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并噻唑类
• 中文名称: [1,3]二氧杂环戊并[4,5-f][1,3]苯并噻唑-6-胺
• 英文名称: [1,3]dioxolo[4’,5’:4,5]benzo[1,2-d]thiazol-6-amine
• 英文别名: [1,3]dioxolo[4',5':4,5]benzo[1,2-d] thiazol-6-amine；[1,3]dioxolo[4',5':4,5]benzo[1,2-d]thiazol-6-amine；2-amino-5,6-methylenedioxybenzo[d]thiazole；[1,3]dioxolo[4',5':4,5]benzo[1,2-d]thiazol-6-ylamine；6-Amino-1,3-dioxolo<4,5-f>benzthiazol；1,3-Dioxolo[4,5-F]benzothiazol-6-amine；[1,3]dioxolo[4,5-f][1,3]benzothiazol-6-amine
• CAS: 50850-94-7
• 化学式: C₈H₆N₂O₂S
• 分子量: 194.214
• InChiKey: GAIRHYOGMGDIGP-UHFFFAOYSA-N

物化性质

• 沸点：
  384.7±50.0 °C(Predicted)
• 密度：
  1.622±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.8
• 重原子数：
  13
• 可旋转键数：
  0
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.12
• 拓扑面积：
  85.6
• 氢给体数：
  1
• 氢受体数：
  5

安全信息

• 海关编码：
  2934999090
• 危险性防范说明：
  P261,P264,P270,P271,P280,P301+P312,P302+P352,P304+P340,P305+P351+P338,P330,P332+P313,P337+P313,P362,P403+P233,P405,P501
• 危险性描述：
  H302,H312,H315,H319,H332,H335
• 储存条件：
  存储条件：2-8°C，避光，惰性气体环境。

反应信息

• 作为反应物：
  描述：

  [1,3]二氧杂环戊并[4,5-f][1,3]苯并噻唑-6-胺 在 盐酸 、 一水合肼 作用下， 反应 5.0h， 生成 6-hydrazinyl-[1,3]dioxolo[4',5':4,5]benzo[1,2-d]thiazole
  参考文献：
  名称：

  Novel Triapine Derivative Induces Copper-Dependent Cell Death in Hematopoietic Cancers

  摘要：

  Triapine, an iron chelator that inhibits ribonucleotide reductase, has been evaluated in clinical trials for cancer treatment. Triapine in combination with other chemotherapeutic agents shows promising efficacy in certain hematologic malignancies; however, it is less effective against many advanced solid tumors, probably due to the unsatisfactory potency and pharmacokinetic properties. In this report, we developed a triapine derivative IC2S (10) with potent antitumor activity. 10 Preferentially inhibited the proliferation of hematopoietic cancers by inducing mitochondria reactive oxygen species production and mitochondrial dysfunction. Unlike triapine, 10 executed cytotoxic action in a copper-dependent manner. 10 Induced up-expression of thioredoxin-interacting protein resulted in decreased thioredoxin activity to permit c-Jun N-terminal kinase and p38 activation and ultimately led to the execution of the cell death program. Remarkedly, 10 showed good bioavailability and inhibited tumor growth in mouse xenograft models. Taken together, our study identifies compound 10 as a copper-dependent antitumor agent, which may be applied to the treatment of hematopoietic cancers.

  DOI：

  10.1021/acs.jmedchem.8b01996
• 作为产物：
  描述：

  1-(3,4-亚甲基二氧苯基)-2-硫脲 在 ammonium hydroxide 、 溴 、 溶剂黄146 作用下， 生成 [1,3]二氧杂环戊并[4,5-f][1,3]苯并噻唑-6-胺
  参考文献：
  名称：

  新的1,4-苯并噻嗪衍生物的合成和生物活性。

  摘要：

  合成了新的2H-1,4-苯并噻嗪-3（4H）-在2位具有（4-苯基-1-哌嗪基）烷基部分的衍生物，并测试了其钙拮抗和钙调蛋白拮抗活性。还评估了自发性高血压大鼠的抗高血压作用。通常，这些化合物是相当弱的钙通道阻滞剂，尽管相反，它们中的许多具有中度至强效的钙调蛋白拮抗活性，以及​​2- [3-（4-（4-氟苯基）-1-哌嗪基]丙基]- 2H-1,4-苯并噻嗪-3（4H）-一衍生物45、74和75显示有效的降压作用。

  DOI：

  10.1248/cpb.39.2888

文献信息

• [EN] TRICYCLIC HETEROARYL-SUBSTITUTED QUINOLINE AND AZAQUINOLINE COMPOUNDS AS PAR4 INHIBITORS<br/>[FR] COMPOSÉS TRICYCLIQUES DE QUINOLÉINE ET D'AZAQUINOLINE À SUBSTITUTION HÉTÉROARYLE INHIBITEURS DE PAR4
  申请人：BRISTOL MYERS SQUIBB CO

  公开号：WO2018013776A1

  公开（公告）日：2018-01-18

  Disclosed are compounds of Formula (I) to (VIII): (I) (II) (III) (IV) (V) (VI) (VII) (VIII) or a stereoisomer, tautomer, pharmaceutically acceptable salt, solvate or prodrug thereof, wherein R3 is a tricyclic heteroaryl group substituted with R3a and zero to 2 R3b; and R1, R2, R3a, R3b, R4, and n are defined herein. Also disclosed are methods of using such compounds as PAR4 inhibitors, and pharmaceutical compositions comprising such compounds. These compounds are useful in inhibiting or preventing platelet aggregation, and are useful for the treatment of a thromboembolic disorder or the primary prophylaxis of a thromboembolic disorder.

  揭示了化合物的结构式（I）至（VIII）：（I）（II）（III）（IV）（V）（VI）（VII）（VIII）或其立体异构体、互变异构体、药学上可接受的盐、溶剂合物或前药，其中R3是一个三环杂芳基，其上取代有R3a和零至2个R3b；R1、R2、R3a、R3b、R4和n在此有定义。还揭示了将这些化合物用作PAR4抑制剂的方法，以及包含这些化合物的药物组合物。这些化合物在抑制或预防血小板聚集方面很有用，并且可用于治疗血栓栓塞性疾病或血栓栓塞性疾病的初级预防。
• [EN] PHENYLIMIDE-CONTAINING BENZOTHIAZOLE DERIVATIVE OR ITS SALT AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME<br/>[FR] DÉRIVÉ DE BENZOTHIAZOLE CONTENANT PHÉNYLIMIDE OU SON SEL ET COMPOSITION PHARMACEUTIQUE LE COMPRENANT
  申请人：YUHAN CORP

  公开号：WO2013043001A1

  公开（公告）日：2013-03-28

  The present invention provides a phenylimide-containing benzothiazole derivative or its pharmaceutically acceptable salt, a process for the preparation thereof, and a pharmaceutical composition comprising the same. The phenylimide-containing benzothiazole derivative or its pharmaceutically acceptable salt can selectively inhibit the protein-protein interaction between KRS and a laminin receptor (LR), thereby inhibiting migration of cancer cells. Therefore, the phenylimide-containing benzothiazole derivative or its pharmaceutically acceptable salt may be usefully applied for preventing or treating the diseases associated with cancer cell metastasis.

  本发明提供了一种含有苯甲酰亚胺基的苯并噻唑衍生物或其药用可接受盐，以及其制备方法和包含其的药物组合物。所述含有苯甲酰亚胺基的苯并噻唑衍生物或其药用可接受盐可以选择性地抑制KRS和层粘连蛋白受体（LR）之间的蛋白质相互作用，从而抑制癌细胞的迁移。因此，含有苯甲酰亚胺基的苯并噻唑衍生物或其药用可接受盐可能被有益地应用于预防或治疗与癌细胞转移相关的疾病。
• PHENYLIMIDE-CONTAINING BENZOTHIAZOLE DERIVATIVE OF ITS SALT AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME
  申请人：YUHAN CORPORATION

  公开号：US20150011528A1

  公开（公告）日：2015-01-08

  Provided is a phenylimide-containing benzothiazole derivative or its pharmaceutically acceptable salt, a process for the preparation thereof, and a pharmaceutical composition comprising the same. The phenylimide-containing benzothiazole derivative or its pharmaceutically acceptable salt can selectively inhibit the protein-protein interaction between KRS and a laminin receptor (LR), thereby inhibiting migration of cancer cells. Therefore, the phenylimide-containing benzothiazole derivative or its pharmaceutically acceptable salt may be usefully applied for preventing or treating the diseases associated with cancer cell metastasis.

  提供一种含有苯基亚胺基的苯并噻唑衍生物或其药用可接受盐，以及其制备方法和包含相同的药物组合物。该含有苯基亚胺基的苯并噻唑衍生物或其药用可接受盐可以选择性地抑制KRS和层粘连蛋白受体（LR）之间的蛋白质相互作用，从而抑制癌细胞的迁移。因此，该含有苯基亚胺基的苯并噻唑衍生物或其药用可接受盐可能被有用地应用于预防或治疗与癌细胞转移相关的疾病。
• 신규한 디플루오로아세트산 유도체 화합물 및 이를 포함한 조성물
  申请人：Pusan National University Industry-University Cooperation Foundation 부산대학교 산학협력단(220040044843) BRN ▼621-82-06530

  公开号：KR20200011270A

  公开（公告）日：2020-02-03

  본 발명은 신규한 디플루오로아세트산 유도체 화합물 및 이를 포함하는 다양한 용도의 조성물에 관한 것으로, 상기 디플루오로아세트산 유도체 화합물은 PPARα, β 또는 γ 중 어느 하나를 활성화시키는 어고니스트로서 작용할 수 있을 뿐만 아니라, 이중 효능 또는 삼중 효능을 나타낼 수 있는 바, 따라서 PPARs이 관여하는 대사성 질환을 보다 효과적으로 예방, 개선 내지 치료할 수 있고, 더 나아가 미백 및 주름 개선 활성, 항염증 및 항산화 효과까지 나타낼 수 있으므로, 다양한 조성물로서 유용하게 활용될 수 있다.

  本发明涉及一种新型的二氟乙酸衍生物化合物及包含它的各种用途的组合物，所述二氟乙酸衍生物化合物可以作为激活PPARα、β或γ中任一种的激动剂，不仅可以发挥单一作用，还可以表现出双重或三重效应，因此可以更有效地预防、改善或治疗与PPARs相关的代谢性疾病，同时还表现出美白和减少皱纹的活性，具有抗炎和抗氧化效果，因此可以作为各种组合物中有用的成分。
• The synthesis of some 4<i>H</i>-pyrimido[2,1-<i>b</i>]benzothiazol-4-ones
  作者：Robert J. Alaimo

  DOI：10.1002/jhet.5570100515

  日期：1973.10

  A series of 8-substituted and 7,8-disubstituted-4-oxo-3-(4H-pyrimido[2,1-b]benzothiazole)carboxylic acids and esters including a 9-aza analog were synthesized from substituted 2-aminobenzothiazoles and diethyl ethoxymethylenemalonate. The 9-aza analog, ethyl 8-methoxy-4-oxo-3-(4H-pyrido[3′,2′:4,5]thiazolo[3,2-a]pyrimidine)carboxylate (56), represents the first preparation of this new heterocyclic ring

  由取代的2-氨基苯并噻唑合成了一系列的8-取代和7,8-二取代-4-氧代-3-（4 H-嘧啶[ 2,1- b ]苯并噻唑）羧酸和酯，包括9-氮杂类似物。和乙氧基亚甲基丙二酸二乙酯。9-氮杂类似物，乙基8-甲氧基-4-氧代-3-（4 H-吡啶基[3'，2'：4,5]噻唑并[3,2- a ]嘧啶）羧酸盐（56）首先准备这个新的杂环。检查了这些化合物的抗寄生虫活性，但是未检测到显着活性。